BDA-366
Selleck Chemicals
SKU:S7849-5MG
Couldn't load pickup availability
BDA-366 is an antagonist of BCL-2 used in studies of Apoptosis. It is especially relevant in apoptosis and cancer models, where defined compound exposure can be linked to caspase-associated cell-death signaling and survival decisions.
By blocking BCL-2, BDA-366 can be used to examine caspase-associated cell-death signaling and survival decisions. This context is compatible with apoptosis, viability, and caspase-readout assays, as well as transcriptional, biochemical, or phenotypic comparisons linked to the annotated pathway state. In apoptosis and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Target-focused assays involving BCL-2
- Pathway perturbation studies connected to Apoptosis
- Receptor-blockade and ligand-competition studies
- Phenotypic profiling in apoptosis and cancer models
Overall, BDA-366 is appropriate when a defined chemical perturbant is needed to connect BCL-2 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Targets:
- BCL-2
- Target Class:
- Other
- Pathways:
- Apoptosis
- Research Area:
- Apoptosis • Cancer
- CAS No.:
- 1909226-00-1
- Molecular Weight:
- 423.5
- Formula:
- C₂₄H₂₉N₃O₄
- SMILES:
- CCN(CC)CC(CNC1=C2C(=C(C=C1)NCC3CO3)C(=O)C4=CC=CC=C4C2=O)O
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.